Imaging of tumor angiogenesis: Functional or targeted?

American Journal of Roentgenology

Volumn 193, Issue 2, 2009, Pages 304-313

  Turkbey, Baris ^a   Kobayashi, Hisataka ^a   Ogawa, Mikako ^a   Bernardo, Marcelino ^a   Choyke, Peter L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Angiogenesis; Functional imaging; Targeted imaging; Tumor angiogenesis

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID VASCULOTROPIN 121 CU 64; ALBUMIN; ARGINYLGLYCYLASPARTIC ACID; BEVACIZUMAB; CARBON 11; CARBON MONOXIDE O 15; CONTRAST MEDIUM; DENDRIMER; ECHISTATIN; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; GADOLINIUM CHELATE; INDIUM 111; IODINE 125; LIPOSOME; MATRIX METALLOPROTEINASE INHIBITOR; POLYASPARTIC ACID; SUPERPARAMAGNETIC IRON OXIDE; TECHNETIUM 99M; TRACER; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; WATER O 15; ZIRCONIUM 89;

ADVANCED CANCER; ANGIOGENESIS; ANTIANGIOGENIC THERAPY; ARTIFICIAL EMBOLISM; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; COLON CANCER; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC IMAGING; DRUG HALF LIFE; ECHOGRAPHY; GYNECOLOGIC CANCER; HUMAN; LUNG NODULE; MOLECULAR IMAGING; MONITORING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT RESPONSE; TUMOR; VASCULAR RESISTANCE; VIRUS PARTICLE;

ANIMALS; CELL LINE, TUMOR; DIAGNOSTIC IMAGING; FEMALE; HUMANS; IMAGE ENHANCEMENT; LYMPHATIC METASTASIS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, X-RAY COMPUTED; TUMOR MARKERS, BIOLOGICAL; ULTRASONOGRAPHY;

EID: 68149165449     PISSN: 0361803X     EISSN: None     Source Type: Journal    
DOI: 10.2214/AJR.09.2869     Document Type: Review

References (80)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 18:1182-1186
2. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003; 3:401-410
3. Cosgrove D. Angiogenesis imaging: ultrasound. Br J Radiol 2003; 76[spec no 1]:S43-S49
4. Hata K, Nagami H, Iida K, Miyazaki K, Collins WP. Expression of thymidine phosphorylase in malignant ovarian tumors: correlation with microvessel density and an ultrasound-derived index of angiogenesis. Ultrasound Obstet Gynecol 1998; 12:201-206 (Pubitemid 28474928)
5. Yang WT, Tse GM, Lam PK, Metreweli C, Chang J. Correlation between color power Doppler sonographic measurement of breast tumor vasculature and immunohistochemical analysis of microvessel density for the quantitation of angiogenesis. J Ultrasound Med 2002; 21:1227-1235 (Pubitemid 35257572)
6. Alcázar JL. Tumor angiogenesis assessed by three-dimensional power Doppler ultrasound in early, advanced and metastatic ovarian cancer: a preliminary study. Ultrasound Obstet Gynecol 2006; 28:325-329
7. Lagalla R, Caruso G, Urso R, Bizzini G, Marasà L, Miceli V. The correlations between color Doppler using a contrast medium and the neoangiogenesis of small prostatic carcinomas. Radiol Med (Torino) 2000; 99:270-275 (Pubitemid 30422503)
8. D'Arcy TJ, Jayaram V, Lynch M, et al. Ovarian cancer detected noninvasively by contrast-enhanced power Doppler ultrasound. BJOG 2004; 111:619-622
9. Hotta N, Tagaya T, Maeno T, et al. Advanced dynamic flow imaging with contrast-enhanced ultrasonography for the evaluation of tumor vascularity in liver tumors. Clin Imaging 2005; 29:34-41 (Pubitemid 40093013)
10. Lamuraglia M, Escudier B, Chami L, et al. To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: pilot study using dynamic contrast-enhanced Doppler ultrasound. Eur J Cancer 2006; 42:2472-2479 (Pubitemid 44442955)
11. Wang Z, Tang J, An L, et al. Contrast-enhanced ultrasonography for assessment of tumor vascularity in hepatocellular carcinoma. J Ultrasound Med 2007; 26:757-762 (Pubitemid 46870343)
12. Korpanty G, Carbon JG, Grayburn PA, Fleming JB, Brekken RA. Monitoring response to anticancer therapy by targeting microbubbles to tumor vasculature. Clin Cancer Res 2007; 13:323-330 (Pubitemid 46121886)
13. Nishida M, Koito K, Hirokawa N, Hori M, Satoh T, Hareyama M. Does contrast-enhanced ultrasound reveal tumor angiogenesis in pancreatic ductal carcinoma? A prospective study. Ultrasound Med Biol 2009; 35:175-185
14. Balleyguier C, Opolon P, Mathieu MC, et al. New potential and applications of contrast-enhanced ultrasound of the breast: own investigations and review of the literature. Eur J Radiol 2009; 69:14-23
15. Ma SH, Le HB, Jia BH, et al. Peripheral pulmonary nodules: relationship between multislice spiral CT perfusion imaging and tumor angiogenesis and VEGF expression. BMC Cancer 2008; 8:186
16. Ippolito D, Sironi S, Pozzi M, et al. Hepatocellular carcinoma in cirrhotic liver disease: functional computed tomography with perfusion imaging in the assessment of tumor vascularization. Acad Radiol 2008; 15:919-927 (Pubitemid 352033551)
17. Sabir A, Schor-Bardach R, Wilcox CJ, et al. Perfusion MDCT enables early detection of therapeutic response to antiangiogenic therapy. AJR 2008; 191:133-139 (Pubitemid 351955217)
18. Li ZP, Meng QF, Sun CH, et al. Tumor angiogenesis and dynamic CT in colorectal carcinoma: radiologic-pathologic correlation. World J Gastroenterol 2005; 11:1287-1291
19. Haider MA, Milosevic M, Fyles A, et al. Assessment of the tumor microenvironment in cervix cancer using dynamic contrast enhanced CT, interstitial fluid pressure and oxygen measurements. Int J Radiat Oncol Biol Phys 2005; 62:1100-1107 (Pubitemid 40884424)
20. Makari Y, Yasuda T, Doki Y, et al. Correlation between tumor blood flow assessed by perfusion CT and effect of neoadjuvant therapy in advanced esophageal cancers. J Surg Oncol 2007; 96:220-229 (Pubitemid 350194620)
21. Miles KA. Perfusion CT for the assessment of tumour vascularity: which protocol? Br J Radiol 2003; 76:S36-S42
22. Choyke PL, Dwyer AJ, Knopp MV. Functional tumor imaging with dynamic contrast-enhanced magnetic resonance imaging. J Magn Reson Imaging 2003; 17:509-520 (Pubitemid 36528666)
23. Tofts PS, Brix G, Buckley DL, et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 1999; 10:223-232 (Pubitemid 29463104)
24. Liu PF, Krestin GP, Huch RA, Göhde SC, Caduff RF, Debatin JF. MRI of the uterus, uterine cervix, and vagina: diagnostic performance of dynamic contrast-enhanced fast multiplanar gradientecho imaging in comparison with fast spinecho T2-weighted pulse imaging. Eur Radiol 1998; 8:1433-1440
25. Jager GJ, Ruijter ET, van de Kaa CA, et al. Dynamic turboFLASH subtraction technique for contrast-enhanced MR imaging of the prostate: correlation with histopathologic results. Radiology 1997; 203:645-652
26. Hoskin PJ, Saunders MI, Goodchild K, Powell ME, Taylor NJ, Baddeley H. Dynamic contrast enhanced magnetic resonance scanning as a predictor of response to accelerated radiotherapy for advanced head and neck cancer. Br J Radiol 1999; 72:1093-1098
27. Barentsz JO, Berger-Hartog O, Witjes JA, et al. Evaluation of chemotherapy in advanced urinary bladder cancer with fast dynamic contrast-enhanced MR imaging. Radiology 1998; 207:791-797 (Pubitemid 28279915)
28. Reddick WE, Taylor JS, Fletcher BD. Dynamic MR imaging (DEMRI) of microcirculation in bone sarcoma. J Magn Reson Imaging 1999; 10:277-285
29. Devries AF, Griebel J, Kremser C, et al. Tumor microcirculation evaluated by dynamic magnetic resonance imaging predicts therapy outcome for primary rectal carcinoma. Cancer Res 2001; 61:2513-2516 (Pubitemid 32685831)
30. Hayes C, Padhani AR, Leach MO. Assessing changes in tumour vascular function using dynamic contrast-enhanced magnetic resonance imaging. NMR Biomed 2002; 15:154-163 (Pubitemid 34213405)
31. Mayr NA, Yuh WT, Arnholt JC, et al. Pixel analysis of MR perfusion imaging in predicting radiation therapy outcome in cervical cancer. J Magn Reson Imaging 2000; 12:1027-1033
32. Thukral A, Thomasson DM, Chow CK, et al. Inflammatory breast cancer: dynamic contrast-enhanced MR in patients receiving bevacizumab-initial experience. Radiology 2007; 244:727-735 (Pubitemid 47292083)
33. Wedam SB, Low JA, Yang SX, et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol 2006; 24:769-777
34. Ocak I, Bernardo M, Metzger G, et al. Dynamic contrast-enhanced MRI of prostate cancer at 3 T: a study of pharmacokinetic parameters. AJR 2007; 189:849; [web]W192-W201
35. Kosaka N, Uematsu H, Kimura H, et al. Assessment of the vascularity of uterine leiomyomas using double-echo dynamic perfusion-weighted MRI with the first-pass pharmacokinetic model: correlation with histopathology. Invest Radiol 2007; 42:629-635 (Pubitemid 47262931)
36. Preda A, Novikov V, Möglich M, et al. MRI monitoring of Avastin antiangiogenesis therapy using B22956/1, a new blood pool contrast agent, in an experimental model of human cancer. J Magn Reson Imaging 2004; 20:865-873 (Pubitemid 39426084)
37. Marzola P, Degrassi A, Calderan L, et al. Early antiangiogenic activity of SU11248 evaluated in vivo by dynamic contrast-enhanced magnetic resonance imaging in an experimental model of colon carcinoma. Clin Cancer Res 2005; 11:5827-5832 (Pubitemid 41170309)
38. Taylor NJ, Lankester KJ, Stirling JJ, et al. Application, of navigator techniques to breath-hold DCE-MRI studies of the liver. In: Proceedings of the International Society of Magnetic Resonance in Medicine 11th scientific meeting. Berkeley, CA: ISMRM, 2003:1306
39. Castro MA, Yao J, Turkbey B, Pang Y, Choyke PL, Thomasson D. Improvement of DCE-MRI images to study liver cancer by means of a deformable registration algorithm. (abstr) Proceedings of the annual meeting of the Radiological Society of North America (RSNA). Chicago, IL: RSNA, 2008: 691
40. Anderson H, Yap JT, Wells P, et al. Measurement of renal tumour and normal tissue perfusion using positron emission tomography in a phase II clinical trial of razoxane. Br J Cancer 2003; 89:262-267 (Pubitemid 36976313)
41. Wells P, Jones T, Price P. Assessment of inter- and intrapatient variability in C15O2 positron emission tomography measurements of blood flow in patients with intra-abdominal cancers. Clin Cancer Res 2003; 9:6350-6356 (Pubitemid 38031819)
42. 18F-FDG PET study. Nucl Med Commun 2007; 28:789-797
43. Longo R, Gasparini G. Anti-VEGF therapy: the search for clinical biomarkers. Expert Rev Mol Diagn 2008; 8:301-314 (Pubitemid 351724709)
44. 18F-fluorodeoxyglucose positron emission tomography in patients with recurrent ovarian cancer: in comparison with vascularity, Ki-67, p53, and histologic grade. Eur Radiol 2007; 17:409-417
45. Bos R, van Der Hoeven JJ, van Der Wall E, et al. Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol 2002; 20:379-387 (Pubitemid 34072519)
46. Zasadny KR, Tatsumi M, Wahl RL. FDG metabolism and uptake versus blood flow in women with untreated primary breast cancers. Eur J Nucl Med Mol Imaging 2003; 30:274-280 (Pubitemid 36686847)
47. 18F-FDG uptake and prognostic impact in lung adenocarcinomas. J Nucl Med 2006; 47:419-425
48. 18F-FDG uptake: is there a contribution of the endothelium? J Nucl Med 2004; 45:461-463
49. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004; 25:581-611 (Pubitemid 39099316)
50. Kowanetz M, Ferrara N. Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin Cancer Res 2006; 12:5018-5022 (Pubitemid 44453326)
51. Middleton G, Lapka DV. Bevacizumab (Avastin). Clin J Oncol Nurs 2004; 8:666-669
52. Lyshchik A, Fleischer AC, Huamani J, Hallahan DE, Brissova M, Gore JC. Molecular imaging of vascular endothelial growth factor receptor 2 expression using targeted contrast-enhanced high-frequency ultrasonography. J Ultrasound Med 2007; 26:1575-1586
53. Lee DJ, Lyshchik A, Huamani J, Hallahan DE, Fleischer AC. Relationship between retention of a vascular endothelial growth factor receptor 2 (VEGFR2)-targeted ultrasonographic contrast agent and the level of VEGFR2 expression in an in vivo breast cancer model. J Ultrasound Med 2008; 27:855-866 (Pubitemid 351913824)
54. Willmann JK, Paulmurugan R, Chen K, et al. US imaging of tumor angiogenesis with microbubbles targeted to vascular endothelial growth factor receptor type 2 in mice. Radiology 2008; 246:508-518
55. Hsu AR, Cai W, Veeravagu A, et al. Multimodality molecular imaging of glioblastoma growth inhibition with vasculature-targeting fusion toxin VEGF121/rGel. J Nucl Med 2007; 48:445-454 (Pubitemid 47604931)
56. Cai W, Chen K, Mohamedali KA, et al. PET of vascular endothelial growth factor receptor expression. J Nucl Med 2006; 47:2048-2056 (Pubitemid 47544993)
57. Nagengast WB, de Vries EG, Hospers GA, et al. In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. J Nucl Med 2007; 48:1313-1319
58. Wang H, Cai W, Chen K, et al. A new PET tracer specific for vascular endothelial growth factor receptor 2. Eur J Nucl Med Mol Imaging 2007; 34:2001-2010 (Pubitemid 350212131)
59. Backer MV, Gaynutdinov TI, Patel V, et al. Vascular endothelial growth factor selectively targets boronated dendrimers to tumor vasculature. Mol Cancer Ther 2005; 4:1423-1429
60. Ruoslahti E. Specialization of tumour vasculature. Nat Rev Cancer 2002; 2:83-90
61. Cai W, Chen X. Antiangiogenic cancer therapy based on integrin alphavbeta3 antagonism. Anticancer Agents Med Chem 2006; 6:407-428
62. 3. Circulation 2003; 108:336-341
63. 3-targeted paramagnetic nanoparticles. Magn Reson Med 2005; 53:621-627
64. Lee HY, Li Z, Chen K, et al. PET/MRI dual-modality tumor imaging using arginine-glycine-aspartic (RGD)-conjugated radiolabeled iron oxide nanoparticles. J Nucl Med 2008; 49:1371-1379
65. 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res 2001; 61:1781-1785
66. Chen X, Park R, Shahinian AH, et al. 18F-labeled RGD peptide: initial evaluation for imaging brain tumor angiogenesis. Nucl Med Biol 2004; 31:179-189 (Pubitemid 38315112)
67. 18F- galacto-RGD in cancer patients. J Nucl Med 2005; 46:1333-1341
68. 3 expression in man. Clin Cancer Res 2006; 12:3942-3949
69. 18F-FDG. J Nucl Med 2008; 49:22-29
70. 18F-AH111585 in breast cancer patients. J Nucl Med 2008; 49:879-886
71. 3 integrin expression. Eur J Nucl Med Mol Imaging 2008; 35:1507-1515
72. 3 in brain tumor xenografts. Cancer Res 2004; 64: 8009-8014
73. 3 in mice using multivalent or monovalent cRGD targeting vectors. Mol Cancer 2007; 6:41
74. 3 in an orthotopic glioblastoma model. Mol Imaging Biol 2006; 8:315-323
75. Li WP, Anderson CJ. Imaging matrix metalloproteinase expression in tumors. Q J Nucl Med 2003; 47:201-208 (Pubitemid 37279156)
76. 18F-labeled matrix metalloproteinase-2 inhibitor. Nucl Med Biol 2003; 30:119-125
77. Medina OP, Kairemo K, Valtanen H, et al. Radionuclide imaging of tumor xenografts in mice using a gelatinase-targeting peptide. Anticancer Res 2005; 25:33-42 (Pubitemid 40470088)
78. 11C]methoxyphenyl) sulfonyl]benzylamino]-3- methylbutanamide. Nucl Med Biol 2004; 31:77-85
79. Bremer C, Bredow S, Mahmood U, Weissleder R, Tung CH. Optical imaging of matrix metalloproteinase-2 activity in tumors: feasibility study in a mouse model. Radiology 2001; 221:523-529 (Pubitemid 33043440)
80. Liu Y, Bellomi M, Gatti G, Ping X. Accuracy of computed tomography perfusion in assessing metastatic involvement of enlarged axillary lymph nodes in patients with breast cancer. Breast Cancer Res 2007; 9:R40 (Pubitemid 350215183)